Amgen Inc (NASDAQ:AMGN) reported second-quarter 2025 financial results that surpassed analyst expectations, though the market reaction has been muted so far. The biotech giant posted revenue of $9.179 billion, narrowly beating the consensus estimate of $9.117 billion. Earnings per share (EPS) came in at $6.02, significantly higher than the $5.39 analysts had projected.
Key Financial Highlights
- Revenue Beat: Actual Q2 revenue of $9.179B vs. $9.117B estimated (0.7% beat).
- Strong EPS Performance: Reported EPS of $6.02 vs. $5.39 expected (11.7% beat).
- Full-Year Estimates: Analysts expect 2025 revenue of $36.086B and EPS of $21.30.
- Q3 Outlook: Revenue is projected at $9.148B with EPS of $5.49.
Despite the earnings beat, shares dipped slightly in after-hours trading, down about 1%. This muted reaction could reflect broader market conditions, profit-taking after recent gains, or investor caution despite the strong numbers. Over the past month, AMGN has risen 3.1%, suggesting some optimism was already priced in.
Press Release Takeaways
CEO Robert Bradway emphasized the company’s progress in delivering innovative medicines and biosimilars, noting investments in long-term growth. The earnings report also highlighted strength in legacy products like Repatha (cholesterol management) and Otezla (psoriasis). Notably, Amgen raised its full-year 2025 guidance, signaling confidence in continued performance.
Market Sentiment vs. Fundamentals
While the earnings beat is positive, the stock’s lack of a strong upward move post-announcement may indicate:
- High Expectations: Investors may have anticipated strong results given recent momentum.
- Macro Factors: Broader market trends or sector-specific headwinds could be weighing on biotech stocks.
- Forward Guidance: Though Amgen raised its outlook, it may not have exceeded already bullish analyst estimates enough to trigger a rally.
For a deeper dive into Amgen’s earnings trends and future estimates, see Amgen’s earnings and estimates page.
Disclaimer: This article is not investment advice. Investors should conduct their own research or consult a financial professional before making decisions.
